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Introduction: Promising Web-based interventions for smokeless tobacco cessation have emerged. We describe a
randomized controlled trial (RCT) testing the relative beneﬁts of adding the nicotine lozenge as an adjunct to the
MyLastDip Web-based smokeless tobacco cessation intervention.
Methods: 407 smokeless tobacco users who wanted to quit were recruited, screened online, and randomly
assigned to one of two conditions: (a) the interactive MyLastDip Web-based intervention (Web Only; n =
202), or (b) thewebsite plus the offer of nicotine lozenges (Web+ Lozenge; n=205). MyLastDip program con-
tent is grouped according to three sequential frames: preparing to quit, quitting, and staying quit. If a participant
reported a lapse then the program would provide tailored content on lessons learned and starting over
(“retooling”). The primary outcome was 7-day point prevalence tobacco abstinence measured at follow-up as-
sessments that occurred 3 months and 6 months post-enrollment.
Results: Assessment completion rates were 71.5% at 3 months, 72.9% at 6 months, and 65.1% for both 3 and 6
months, and did not differ by condition. Using Intent to Treat analyses, theWeb + Lozenge condition was asso-
ciatedwith a signiﬁcantly higher 7-day point prevalence tobacco abstinence rate than theWeb Only condition at
3 months (43.4% vs. 29.7%, p= .004), at the combined 3 and 6 month assessment of repeated point prevalence
(35.6% vs. 23.3%, p = .007), but not at 6 months (44.4% vs. 35.1%, p = .057). Similar results were obtained for
smokeless tobacco abstinence. Participants reported being satisﬁedwith their programs and theWeb+ Lozenge
condition participants visited theMyLastDip programmore often (p b .001). A composite engagementmeasure of
the number and duration of program visits was positively related to 6-month tobacco abstinence (p= .009).
Conclusions: Consistent with previous research, the MyLastDip Web-based tobacco cessation intervention en-
couraged long-term levels of tobacco and smokeless tobacco abstinence. The addition of nicotine lozenges signif-
icantly improved both participant engagement and self-reported 7-day point prevalence tobacco abstinence at 3
months and when considering 3- and 6-month repeated point prevalence tobacco abstinence.© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
Smokeless tobacco includes use of either chewing tobacco (user
chews tobacco typically packaged in foil pouches); moist snuff (ﬁnely
ground tobacco not chewed but placed between the cheek and gums
and packaged in tins or cans); and snus,moist snuff processed to reduce
cancer-causing nitrosamines, marketed in small tea bags packaged in
tins. Smokeless tobacco does not include electronic or e-cigarettes or
waterpipes.776 Millrace Drive, Eugene, OR
. This is an open access article underSmokeless tobacco is a serious public health problem in the U.S.
(USDHHS, 2012) and it is used by almost 8 million American adults
(7.1% of men and 0.4% of women) (SAMHSA, 2013). Although using
smokeless tobacco is less harmful than smoking cigarettes (Lee and
Hamling, 2009), both the U.S. Department of Health and Human Ser-
vices (U. S. National Toxicology Program, 2014) and the World Health
Organization (International Agency for Research on Cancer, 2012)
have concluded that it contains known human carcinogens. For exam-
ple, studies indicate that smokeless tobacco is a cause of cancer of the
throat, stomach (Mattson and Winn, 1989), and pancreas (Alguacil
and Silverman, 2004).
Our research group has developed and evaluated eHealth smokeless
tobacco cessation interventions — the ChewFree program (Seversonthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2013). Both are fully automated Web-based interventions designed to
be used on personal computers, and incorporate tailored content,
graphics, interactive activities, practice audios, and testimonial videos,
and have used Web forums. Both programs have displayed highly en-
couraging results in terms of all-tobacco abstinence.
Another thrust in smokeless tobacco cessation research has
examined the use of nicotine lozenges. Nicotine lozenges are part
of the larger family of nicotine replacement therapy (NRT) products
which have been found to increase smoking cessation treatment
efﬁcacy by 50% to 70% (Stead et al., 2012) but they have shown
equivocal beneﬁts as adjuncts to smokeless tobacco cessation
(Ebbert et al., 2011). Over a number of studies (Ebbert et al., 2007;
Ebbert et al., 2010a; Ebbert et al., 2009, 2010b, 2013; Severson
et al., in press), our team has examined the effects and acceptability
of following a regimen of using nicotine lozenges by smokeless
tobacco users who want to quit. In one study (Ebbert et al., 2013)
we found that using nicotine lozenges attenuated the experience of
withdrawal symptoms, and this was related to greater short-term
tobacco abstinence. In a more recent smokeless tobacco cessation
trial (Severson et al., in press), we examined the extent to which loz-
enges beneﬁted from the support provided in telephonic coach calls.
Results showed that combining nicotine lozenges and phone
counseling signiﬁcantly increased tobacco abstinence rates com-
pared to either intervention alone (Severson et al., in press).
This present studywas informed by both of the previously described
research threads— Internet intervention and nicotine lozenges. Smoke-
less tobacco userswho sought help to quit via an Internet programwere
randomized to the Web condition or the Web plus the offer of free
lozenges. Our hypothesis was that participants assigned to the Web +
Lozenge condition would have signiﬁcantly increased abstinence of
all-tobacco and smokeless tobacco abstinence compared to the Web
Only condition.
2. Methods
2.1. Participants
Participant recruitment for the current study occurred from January,
2013 to July, 2013. We used a nationwide Google AdWords online
marketing campaign to recruit an average of 15 study participants
each week until 407 study participants were enrolled. The campaign
(both in online listings and content on the study marketing page) de-
scribed a study that would compare the use of an online individualized
(tailored) smokeless tobacco cessation program both with – and with-
out – the use of nicotine lozenges. Individuals who indicated interest
in participating pressed a button on theMyLastDip.com projectmarket-
ing website to initiate the online screening procedure.
Interested individuals followed an online enrollment protocol hav-
ing seven sequential steps: (1) registration, (2) screening, (3) informed
consent, (4) sharing contact information, (5) baseline assessment,
(6) randomization to condition, and (7) an email invitation to visit the
website and offer of lozenges. The time required to complete this proto-
col was approximately 10–15 min.
An automated registration procedure was triggered when respon-
dents pressed a “sign up” button on the project marketing website,
which asked them to submit their email address. Respondent requests
with email addresses not already in our database of the current study
and our other ongoing studies were then sent an email invitation with
login information to start the online screening process. In order to be el-
igible for possible inclusion, respondents submitting screening data in-
dicated that they were: (1) at least 18 years old, (2) used smokeless
tobacco on a daily basis for at least 1 year; (3) agreed to quit using to-
bacco within the next month, (4) a U.S. resident, and (5) could read En-
glish. Respondentswere excluded if they endorsed any of the following:
(1) used other behavioral or pharmacologic tobacco treatmentprograms for tobacco cessation or reduction during the previous
30 days; (2) had another household member participating in the
study; or (3) reported any of a series of medical/health conditions that
were precautions related to our use of nicotine lozenge: unstable angi-
na, myocardial infarction within the previous 6 months, cardiac dys-
rhythmia other than medication-controlled atrial ﬁbrillation or
paroxysmal supraventricular tachycardia (PSVT), hypertension with
blood pressure of ≥180 systolic or ≥100 diastolic, phenylketonuria
(PKU); or currently pregnant or nursing. Individuals were also excluded
whosemailing addressmatched one already recorded in our database of
prior respondents. Individuals deemed ineligible aswell as those not in-
terested in participating were offered free access to the MyLastDip ces-
sation program (Danaher et al., 2013), which wasmade freely available
in a non-research mode (without assessments).
The study protocol was approved by Oregon Research Institute's
(ORI) Human Subjects Institutional Review Board (approval #
FWA00005934).
2.2. Study design
A randomization sequence vectorwas used to randomly assign eligi-
ble individuals to one of the two experimental conditions:
(1) MyLastDip only (Web Only; n= 202)
MyLastDip program is an engaging and interactiveWeb-based
intervention. Program content is grouped according to three
sequential frames: preparing to quit, quitting, and staying
quit. If a participant reported a lapse then the program
would provide tailored content on lessons learned and
starting over (“retooling”). The program incorporated activi-
ties designed to encourage participant engagement, including
the creation of a personal quitting plan. Participants were able
to create personal lists (e.g., reasons for quitting), calculate
how much money they would save once quit, watch videos
of smokeless tobacco quitters who successfully overcame
challenges to quit, listen to relaxation audios and videos,
choose a quit date and method, and create a personal quitting
contract (Figs. 1 and 2). The program also included a Resource
section that described the ingredients of smokeless tobacco,
the role of nicotine, health effects of using smokeless tobacco,
prescription medications, types of nicotine replacement ther-
apies (NRT), fake chew or herbal snuff, and links to websites
that contained additional information.
Automated email reminders were sent to participants in order
to encourage their use of the program. For example, if a partic-
ipant did not indicate a quit date, then they were sent a re-
minder email to encourage them to visit the website in order
to choose a quit date and beneﬁt from other useful strategies.
Supportive emails were also sent 2 days, 1 week, and 2 weeks
after their quit dates. Some of the email content provided a
general endorsement of the use of NRT products. Emails
were also sent to prompt completion of scheduled follow-up
assessments. Additional details regarding the MyLastDip pro-
gram can be found in our prior report (Danaher et al., 2013).
The version of the program used for the current trial was up-
dated so that it was appropriate for use by older adults rather
than the study population of 14–25 year olds in the original
study.
(2) MyLastDip plus Lozenges (Web + Lozenge; n = 205)
In addition to being invited to use the MyLastDip program,
participants assigned to the Web + Lozenge condition were
mailed 2 boxes of Nicorette® Lozenges (4 mg; 108 lozenges
per box). Written instructions were provided describing the
tapering schedule to use for taking lozenges: weeks 1 to 6 (1
lozenge every 1–2 h), weeks 7 to 9 (1 lozenge every 2–4 h),
and weeks 10 to 12 (1 lozenge every 4–8 h). During the ﬁrst
Fig. 1.MyLastDip program features.
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project toll-free phone line in order to obtain up to a maxi-
mum of 12 additional free boxes of lozenges in units of 2
boxes per request. In addition to the pattern of emails noted
earlier for the Web Only condition, participants in this condi-
tion received emails that reinforced the rationale for using
lozenges (“Remember, using the lozenges regularly helps
you control cravings before they occur.”) and provided usage
instructions tailored to the timing of the tapering schedule.2.3. Assessment plan and measures
All participants completed a baseline assessment and were asked to
complete follow-up assessments scheduled to occur 3 and 6 months
following enrollment. All assessments were available online although
research staff called participants if assessments were not completed
within 2 weeks of their scheduled date. Participants received $15 for
completing each follow-up assessment and an additional $25 for com-
pleting both assessments.
The baseline assessment measured socio-demographics (age, gen-
der, race/ethnicity, marital status, educational background), smokeless
tobacco usage variables (years of use, number of quit attempts (…seri-
ous attempt to quit using smokeless tobacco more than 24 h in the last 12
months), amount of use, friends' use), tobacco dependence, readiness
to quit, depression status, alcohol consumption, and anticipated partner
support for quitting.
Partner support was assessed by asking “How supportive do you
expect your partner to be of your effort to quit tobacco?” which they
rated using 1= Not at all supportive, 2 = Somewhat supportive, 3 = Sup-
portive, and 4 = Very supportive. Dependence was assessed two ways.
First, we used the Severson Smokeless Tobacco Dependence Scale
(Ebbert et al., 2012) that has scores ranging from0 to 19 (larger values in-
dicating higher dependence). Secondly, dependence was also measured
using a single item, asking if the ﬁrst morning use occurs within 30 min
of waking. This measure has been found to be a predictor in our prior re-
search and has been singled out for its predictive power for smoking ces-
sation (Baker et al., 2007).Readiness to quit was assessed using the contemplation ladder
(Biener and Abrams, 1991) adapted for smokeless tobacco cessation
using an 11-point Likert scale with 1 = Not ready to quit, 3 = Should
consider quitting someday, 5= Should quit but not quite ready, 7= Think-
ing about cutting down or quitting, 9 = Have cut down and seriously con-
sidering quitting, and 11 = Ready to quit now. Participant self-efﬁcacy
was assessed using the item that asked “How conﬁdent are you that
you will not be using any tobacco a year from now?” and used a ﬁve-
point Likert scale: 1 = Not at all conﬁdent, 3 = Somewhat conﬁdent,
and 5 = Completely conﬁdent. Participant depression status was
assessed using the two-item Patient Health Questionnaire (PHQ-2;
Kroenke, Spitzer, & Williams, 2003) that asked “Over the past two
weeks, how often have you been bothered by any of the following prob-
lems?” using two items: “Feeling down, depressed or hopeless” and
“Little interest or pleasuring in doing things?” The assessment
was scored as the overall sum of the responses scored as 0 = Not at
all, 1 = Several days, 2 = More than half the days, and 3 = Nearly
every day. Alcohol status was assessed by asking an item used to screen
problem drinking status (NIAAA, 2005): How many times per month do
you drink more than 3–4 drinks on a single occasion?
Primary tobacco outcomes were self-reported 7-day point preva-
lence tobacco use measured at baseline and the 3- and 6-month
follow-up assessments. These outcomes considered “all tobacco” de-
ﬁned as self-reported non-use of smokeless tobacco, cigarettes, cigars,
and pipes. We also assessed smokeless tobacco abstinence separately.
Secondary tobacco outcomes assessed reduced smokeless tobacco use
(number of cans/pouch used per week), and the number of quit at-
tempts since enrolling in the project.
Lozenge usage in theWeb+Lozenge conditionwas assessedwith the
question: “Since you received the nicotine lozenges, have you been using
them (None of the days, Few days, Less than half of the days, More than
half of the days, and Most days)” and “On the days that you used the loz-
enges, howmuch of each day did you use them?” (I didn't use lozenges, Little
of the day, Less than half the day,More than half the day,Most of the day).
Requests for supplemental lozenges were recorded by project staff.
Program usability was measured at the 3-month follow-up using a
6-point scale: Very difﬁcult to Very easy. Acceptability was measured
by asking participants if they would recommend the program to friends
or family members who use chew/snuff. Additional usability items
Fig. 2.MyLastDip screenshot.
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Lozenge condition.
Usage of theMyLastDipwebsite over the entire course of the program
was measured unobtrusively for all participants including the number of
visits, the duration of these visits, and speciﬁc webpages visited.
2.4. Statistical analyses
SPSS (version 19) was used for all statistical analyses.
Post hoc sensitivity analyses were conducted using G*Power 3.1
(Erdfelder et al., 1996; Faul et al., 2007) to identify the detectable effect
sizes for each outcome evaluated. For primary outcome measures, the
sensitivity analysis was evaluated as a two-tailed test, the sample size
available for each time point (3 months, 6 months, and both 3 and 6
months) and analysis type (Complete Case and ITT), statistical power
set at 1− β= .90, and an adjusted signiﬁcance level, also referred to as
an error probability, of α= .004 (.05/12) to accommodate the number
of tests used to evaluate the all tobacco and smokeless tobacco primaryoutcome measures. For secondary outcome measures, the sensitivity
analysis was evaluated as a two-tailed test, with the sample size available
for each analysis (3month, 6month; Complete Case), statistical power set
at 1− β= .90, and an adjusted signiﬁcance level, of α= .025 (.05/2) to
accommodate the evaluation at each time point (3 month and 6 month).
Primary TobaccoOutcome Analyses assessed 7-day point prevalence
abstinence for all tobacco aswell as for smokeless tobaccouse by includ-
ing analysis of Complete Cases (participants who completed assess-
ments) and Intent to Treat (ITT) imputation analysis (missing cases
considered to be using tobacco). Results were analyzed separately for
the 3- and 6-month follow-up assessments as well using a repeated
point prevalence measure that combined 3- and 6-month assessments
as a measure of more lasting abstinence. Secondary analyses assessed
reductions in smokeless tobacco usage (number of cans, pouches, or
tins used per week from baseline to follow-up) and number of quit at-
tempts since project enrollment among participants who continued to
use tobacco. Reduced usage was calculated as a dichotomous item de-
rived from the amount of usage reported at baseline and follow-up,
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up and a 0 indicating the same or an increase in usage from baseline to
follow-up. Secondary outcomes were assessed using ANOVA and Chi-
Square analyses.
Possible predictors of tobacco outcomes were assessed using a two-
step procedure. First, a univariate binary logistic regression was used to
test the baseline participant characteristics as predictors of tobacco ab-
stinence at the combined 3- and the 6-month assessments. Those pre-
dictors reaching signiﬁcance on the univariate test were then included
in a multivariate binary logistic regression test using backwards elimi-
nation to remove nonsigniﬁcant variables. To identify any differential
effects of the intervention on the prediction of these outcomes themul-
tivariate test included treatment condition as well as the interaction of
condition with sample characteristics.
2.4.1. Program acceptability and usage
Program usage and acceptability were assessed using ANOVA, Non-
parametric Mann–Whitney U and Chi-Square analyses. Logistic regres-
sions were used to evaluate program usage by the measure of tobacco
abstinence at the 6-month assessment. Website program engagement
was measured using the composite measure deﬁned as the mean of
the z score transformations of visits (number) and duration (minutes)
(Danaher et al., 2006).
3. Results
Of the 407 study participants, 291 (71%) completed the 3-month
follow up assessment (141 or 48.5% using the online assessment and
150 or 51.5% via phone calls). The 6-month follow-up assessment
was completed by 297 (73%) participants (165 or 55.6% using the on-
line assessment and 132 or 44.4% via phone calls). A total of 265
(65%) completed both assessments. Assessment completion rates
did not vary by condition or sample characteristics (see CONSORT di-
agram, Fig. 3).
Participant characteristics at baseline, described in Table 1, show
that the sample was nearly all male and approximately 35 years of
age. These ﬁndings are consistentwith our prior smokeless tobacco ces-
sation studies (e.g., Severson et al., 2008). No differences on baseline
participant characteristics were found between the two conditions.
3.1. Tobacco outcomes
ITT results for 7-day point prevalence tobacco abstinence across
conditions were 36.6% (149/407) at 3 months, 39.8% (162/407) at 6
months, and 29.5% (120/407) considering both 3 and 6 months. ITT
results for smokeless tobacco abstinence were only slightly higher:
39.8% (160/407) at 3 months, 42.5% (173/407) at 6 months, and
34.9%, (130/407) at both 3 and 6 months.
3.1.1. Tobacco outcomes by condition
Using Cohen's (1988) guidelines, the analyses of primary and sec-
ondary outcome measures were adequately powered to detect small
to medium sized effects between groups.
Table 2 describes the self-reported tobacco abstinence results (7-day
point prevalence) across the two follow-up assessments as well as for
repeated point prevalence (both 3- and 6-months follow-up). The top
panel shows results for all tobacco and the bottom panel shows results
for smokeless tobacco. Participants in the Web + Lozenge condition
displayed signiﬁcantly greater tobacco abstinence than those in Web
Only at 3months and at both 3 and 6month repeated point prevalence:
3months: OR=1.816 [95% CI: 1.206, 2.734], p= .004; 6months: OR=
1.473 [95% CI: 0.988, 2.195], p= .057; repeated point prevalence: OR=
1.824 [95% CI: 1.182, 2.0], p= .007. The results were similar for smoke-
less tobacco abstinence.
For participants who did not achieve repeated point abstinence, 70%
(91/130) reported reductions in smokeless tobacco used betweenbaseline and 3-month follow-up and 79% (98/124) reported reductions
between baseline and 6-month follow-up. Of the participants reporting
ﬁve or more cans or pouches per week, 76% (54/71) reported a reduc-
tion in use at 3 months and 81% (58/72) at 6 months. Reductions in
use did not differ by condition. Continuing smokeless tobacco users re-
ported 2.79 (SD=1.8) quit attempts since enrolling in the project at the
3-month follow-up and 3.27 quit attempts (SD = 1.7) at the 6-month
follow-up. Participants in the Web + Lozenge condition reported
more quit attempts since enrolling in the project at the 3-month
follow-up assessment compared to the Web Only condition (Web +
Lozenge: M = 3.17, Web Only: M = 2.47; F(1,129) = 4.81, p= .030).
However, the number of quit attempts between baseline and the 6-
month follow-up did not differ by condition.3.2. Predictors and moderators of tobacco outcomes
An analysis of predictors revealed that repeated point tobacco absti-
nence at 3 and 6 months was more likely to be reported by participants
who were not current smokers (β= −2.64; p = .012; OR = 0.0712
[0.009,0.560]), those who have smoked less than 100 cigarettes in
their lifetime (β=−0.583; p= .027; OR = 0.558 [0.333, 0.937]), and
those with higher self-efﬁcacy in their ability to quit (β= 0.375; p =
.0008; OR = 1.456 [1.102,1.923]). However, when the variables were
evaluated as moderators, no effects were detected.3.3. Program acceptability and engagement
3.3.1. Participant use of the MyLastDip program
Study participants spent an average of 25.23 min viewing the
website (median = 15 min, SD = 31.2 min, range = 0–232 min) and
made 2.35 visits (median=1 visit, SD=2.6 visits, range=0–18 visits)
from baseline to the 6-month follow-up. Thirty-two of the participants
(8%; 32/407) never visited the Web intervention (Web Only = 5.9%,
12/202; Web + Lozenge = 9.8%, 20/205), 43.0% (175/407) visited the
program only once, and 41.2% (200/407) visited multiple times. Partic-
ipants in the Web + Lozenge condition visited more times than Web
Only (Z=3.59, p b .001); there were no between-condition differences
in the duration of website visits. For complete cases, the engagement
composite (all program visits and their duration) was positively related
to tobacco abstinence: 3-month assessment (β = 0.414; p = .003;
OR = 1.513 [1.156, 1.981]), 6-month assessment (β = 0.363; p =
.009; OR = 1.437 [1.095, 1.8836]), and at both 3- and 6-month assess-
ments (β= 0.364; p= .015; OR = 1.439 [1.073, 1.931]).3.3.2. Participant use of lozenges
Of the participants who were offered lozenges, 22.92% (47/205)
asked to receive supplemental lozenges during the course of the
program. Those who requested additional lozenges were more likely
to report tobacco abstinence at 3 months, χ2 (1, n = 153) = 5.18,
p = .023, OR = 2.45, 95% CI [1.12, 5.37], and 6 months, χ2 (1, n =
154)= 5.18, p= .041, OR=2.20, 95% CI [1.02, 4.71]. Of the 127 of par-
ticipants who reported using the nicotine lozenges at the 3 month
follow-up assessment, 58.3% (74/127) reported that they had used the
lozenges on a “consistent basis” operationally deﬁned as using lozenges
more than one-half of all days and more than one-half of each of those
days when used. In terms of rated helpfulness of lozenges, 87.4% of
these participants (111/127) reported the lozenges were somewhat,
very or extremely effective. A few participants reported moderate or se-
vere symptoms associated with using lozenges: 7.2% headache, 5.6%
nausea, 11.3% ﬂatulence, 6.5% hiccups, 12.9% heartburn, 7.2% sleep dis-
turbance, 3.2% diarrhea, 18.2% reported decreasing their lozenge use
because of side effects, and 8.3% reported discontinuing lozenge use as
a result.
Fig. 3. CONSORT diagram.
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We found that including nicotine lozenges as an adjunct to an effec-
tiveWeb-based smokeless tobacco cessation intervention modestly but
signiﬁcantly improved long-term tobacco abstinence at the 3-month
follow-up but only approached statistical signiﬁcance at the 6-month
assessment. Inspection of these data indicates that the Web + Lozenge
condition maintained tobacco abstinence from 3 to 6 months (43.4% to44.4%) whereas the Web Only condition improved over time (29.7% to
35.1%), attributable to the net increase in 11 quitters in the Web Only
condition compared to a net increase of just 2 quitters in the Web +
Lozenge condition.
These overall results are consistent with our previous studies that
have shown that nicotine lozenges can be helpful for smokeless tobacco
cessation, likely attributable to the lozenges helping to reduce the expe-
rience of withdrawal symptoms. Our ﬁndings also align well with
Table 1
Participant characteristics at baseline by condition.a
Characteristics Web Only
N= 202
Web + Lozenge
N= 205
Total
N= 407
Age: M (SD) 35.31 (10.4) 35.07 (10.3) 35.19 (10.3)
Male: n (%) 199 (98.5) 198 (96.6) 397 (97.5)
Married or have long-term
partner: n (%)
172 (85.1) 174 (84.9) 346 (85.0)
Race/ethnicity: n (%)
White 186 (94.4) 196 (95.6) 382 (95.0)
Other 11 (5.6) 9 (4.4) 20 (5.0)
Education: n (%)
Not high school graduate 4 (2.0) 2 (1.0) 6 (1.5)
High school graduate 100 (49.5) 119 (58.0) 219 (53.8)
College graduate 82 (40.6) 65 (31.7) 147 (36.1)
Post graduate degree 16 (7.9) 19 (9.3) 35 (8.6)
Days can/pouch lasts: n (%)
Less than one day 25 (12.4) 32 (15.6) 57 (14.0)
1 day 77 (38.1) 87 (42.4) 164 (40.3)
2 days 63 (31.2) 40 (19.5) 103 (25.3)
3 days 28 (13.9) 21 (10.2) 49 (12.0)
4 or more days 9 (4.5) 25 (12.2) 34 (8.4)
Cans/week: n (%)
1–2 cans or pouches a week 27 (13.4) 41 (20.0) 68 (16.7)
3–4 cans or pouches a week 58 (28.7) 39 (19.0) 97 (23.8)
5 or more cans or pouches a week 117 (57.9) 125 (61.0) 242 (59.5)
No. years using smokeless
tobacco: M (SD)
15.42 (10.5) 13.96 (9.6) 14.69 (10.1)
Tobacco dependence
Use smokeless tobacco ≤30 min
waking: n (%)
111 (55.0) 112 (54.6) 223 (54.8)
Tobacco dependence scale: M (SD) 11.91 (3.7) 11.28 (3.6) 11.59 (3.6)
Current smoking: n (%) 13 (6.4) 16 (7.8) 29 (7.1)
≥100 cigs. smoked lifetime: n (%) 89 (44.1) 91 (44.4) 180 (44.2)
No. quit attempts in last year: M (SD) 1.76 (1.5) 1.81 (1.7) 1.79 (1.6)
5 best friends use smokeless: M (SD) 1.91 (1.6) 1.81 (1.4) 1.86 (1.5)
Readiness to quit: M (SD) 9.82 (1.8) 9.65 (1.9) 9.73 (1.8)
Self-efﬁcacy in not using tobacco
in 1 year: M (SD)
2.48 (0.9) 2.56 (1.0) 2.52 (0.9)
Expected support from
partner: n (%)
160 (93.0) 160 (92.0) 320 (92.5)
Depression status: M (SD) 1.36 (1.57) 1.21 (1.51) 1.54 (1.29)
How many times per month do you
drink more than 3–4 drinks on a
single occasion: M (SD)
3.56 (4.9) 3.76 (5.1) 3.66 (5.0)
a Participants were able to refuse to answer any question. Sample for all data was 407
except for expected support for which n= 346.
Table 2
Self-reported 7-day point prevalence tobacco abstinence at follow-up.
3 months, n/N
(%)
6 months, n/N
(%)
3 and 6 months, n/N
(%)
All tobacco
Intent-to-treat analyses
(ITT)
Web Only 60/202 (29.7)** 71/202 (35.1) 47/202 (23.3)**
Web + Lozenge 89/205 (43.4) 91/205 (44.4) 73/205 (35.6)
Complete case analyses
Web Only 60/138 (43.5)* 71/142 (50.0) 47/125 (37.6)*
Web + Lozenge 89/153 (58.2) 91/155 (58.7) 73/140 (52.1)
Smokeless tobacco
Intent-to-treat analyses
(ITT)
Web Only 67/202 (33.2)* 79/202 (39.1) 53/202 (26.2)*
Web + Lozenge 93/205 (45.4) 94/205 (45.9) 77/205 (37.6)
Complete case analyses
Web Only 67/137 (48.9)* 79/142 (55.6) 53/125 (42.4)*
Web + Lozenge 93/153 (60.8) 94/155 (60.6) 77/140 (55.0)
Differences between conditions at assessments and at both 3- and 6-months: *p b .05, **p
b .01.
75B.G. Danaher et al. / Internet Interventions 2 (2015) 69–76published accounts that adding nicotine lozenges to a smoking cessa-
tion program can improve abstinence outcomes (Shiffman et al., 2002;
Stead et al., 2012).
It was encouraging that greater than 70% of study participants com-
pleted each individual follow-up assessment (for all 407 participants:
71.5% at 3 months; 73.0% at 6 months) and that 65.1% completed both
3- and 6-month assessments. This level of assessment completion is
consistent with the follow-up completion results reported for other
Web-based smokeless tobacco cessation intervention RCTs (Danaher
et al., 2013; Danaher et al., 2014; Severson et al., 2008) and somewhat
higher than some smoking cessation studies (e.g., Bricker et al., 2013;
McKay et al., 2008; Munoz et al., 2009; Smit, de Vries and Hoving,
2012) but lower than others (e.g., Graham et al., 2011).
Engagementwith theWeb intervention in the current study (all par-
ticipants:median number of visits and total visit duration:mean=2.35
visits, median= 1 visit, mean= 25.23min) was highly consistent with
the results of the earlier RCT of MyLastDip (Danaher et al., 2013):
mean=2.47 visits,median=1visit, mean=26.34min.Unfortunately,
many smoking cessation interventions (e.g., McClure et al., 2013;
Strecher et al., 2008) have not included similar participation engage-
mentmetrics although one study (Richardson et al., 2013) reportedme-
dian website visits = 2 and median total minutes duration = 32.
Nonetheless, it is reasonable to assume that more participants wouldhave beneﬁted had they more fully engaged in their cessation program.
Previous research on Web-based smokeless tobacco cessation has
shown a dose–response relationship favoring tobacco abstinence
(Danaher et al., 2008).
This study was not designed to separate the active ingredient and
possible expectancy effects of the lozenge. However, from an applied
perspective, this distinction does not matter. Our data do suggest that
providing more than 2 weeks of lozenges would be beneﬁcial. Like our
prior studies on smokeless tobacco cessation,we did not validate partic-
ipant self-reports with biochemical measures. This decision was in-
formed by Glasgow et al. (1993) that biochemical validation in large
low-intensity intervention trials can be impractical, negatively impact
recruitment, and not likely differentially affect results by condition.
While we acknowledge that our resultsmay overestimate the actual ab-
solute abstinence rates, we do not expect that there would be differen-
tial misreporting by study condition.
The observed abstinence levels combined with the high reach of
Web-based program point to the potential public health impact and
signiﬁcance for these smokeless tobacco cessation interventions. They
could be incorporated into stepped care tobacco cessation programs
(Abrams et al., 1996) as well as an important option in established
tobacco Quitline services (Abrams et al., 2010; Danaher et al., 2014;
Graham et al., 2011). However, the cost of lozenges (their purchase
price, shipping and handling costs)will need to be consideredwhen de-
ciding to use them as treatment adjuncts.
Future research possibilities could examine whether interventions
like MyLastDip might be effective for snus users who want to quit
(Toftgard et al., 2010). In addition, a larger effectiveness trial with anon-
going Internet smokeless tobacco cessation programwould be a logical
next step.
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